Breaking News: Silo Pharma Takes Action Against Chronic Pain and Fibromyalgia with SP-26
A Pharmacokinetic and Tolerability Study
Key preclinical milestone for novel, non-opioid extended-release pain therapeutic
SARASOTA, FL, Dec. 18, 2024 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced the initiation of a pharmacokinetic (PK) and tolerability study in partnership with its contract research organization (CRO), AmplifyBio. The study is designed to assess the pharmacokinetics of Silo’s dissolvable ketamine-based injectable implant, SP-26, in a minipig model.
Chronic pain and fibromyalgia are conditions that affect millions of people worldwide, causing significant impact on quality of life. Traditional treatments for these conditions often involve the use of opioids, which come with a high risk of dependence and potential for abuse. Silo Pharma’s SP-26 aims to provide a novel, non-opioid solution for managing chronic pain and fibromyalgia, offering extended-release relief with lower risk of adverse effects.
The initiation of a pharmacokinetic and tolerability study marks a significant milestone in the development of SP-26, demonstrating Silo Pharma’s commitment to advancing innovative treatments for chronic pain conditions. By conducting this study in partnership with a reputable contract research organization, Silo Pharma is ensuring that the safety and efficacy of SP-26 are rigorously evaluated before moving forward with further clinical trials.
SP-26’s dissolvable ketamine-based injectable implant offers a promising alternative to traditional pain management approaches, leveraging the therapeutic benefits of ketamine in a controlled-release formulation. This novel delivery system has the potential to revolutionize the treatment of chronic pain and fibromyalgia, providing patients with a more effective and safer option for long-term relief.
As Silo Pharma continues to progress with the development of SP-26, the results of the pharmacokinetic and tolerability study will be closely monitored by the scientific and medical communities. If successful, SP-26 could represent a game-changing therapeutic option for individuals suffering from chronic pain and fibromyalgia, offering hope for a future where non-opioid treatments are the standard of care.
How This Will Affect Me:
As a potential treatment for chronic pain and fibromyalgia, the development of SP-26 could have a direct impact on individuals who are currently managing these conditions. If SP-26 proves to be safe and effective in clinical trials, it may offer a new and improved treatment option for those seeking relief from chronic pain without the risks associated with opioid use.
How This Will Affect the World:
The introduction of SP-26 as a non-opioid extended-release pain therapeutic could have far-reaching effects on the global healthcare landscape. By providing a safer and more effective alternative to traditional pain management approaches, SP-26 has the potential to improve the quality of life for millions of people worldwide who are living with chronic pain and fibromyalgia.
Conclusion:
Silo Pharma’s SP-26 represents a promising advancement in the treatment of chronic pain and fibromyalgia, offering a novel non-opioid solution that has the potential to transform the way these conditions are managed. As the pharmacokinetic and tolerability study progresses, the scientific and medical communities are eagerly awaiting the results, hopeful for a future where safer and more effective treatments are available for individuals in need.
